YMB YM Bio.'b'ser1

    YM BioSciences to present results of Norelin(TM) study at Cancer

    Vaccines/Adjuvants/Delivery 2005 Congress in Lisbon

 

    MISSISSAUGA, ON, Sept. 5 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM,

AIM:YMBA), the cancer product development company, today announced that it

will present positive clinical trial results for its anti-GnRH prostate cancer

vaccine, Norelin(TM), at the "Cancer Vaccines/Adjuvants/Delivery for the Next

Decade" conference in Lisbon, Portugal September 5-7, 2005.

    Norelin(TM) is a unique, biological approach to the management of hormone

levels in sex-hormone driven cancers and is initially targeting early stage,

hormone-sensitive prostate cancer (HSPC). The drug is a fusion protein that

combines a proprietary protein sequence in a potent adjuvant formulation. The

formulation could represent a well-tolerated and long-lasting control of

testosterone and PSA in hormone-dependent patients with prostate cancer

thereby affording treatment to a larger population of HSPC patients. That

would include those subject to "watchful waiting".

    David Allan, Chairman and Chief Executive Officer of YM BioSciences

stated, "We are very encouraged by the positive results from this study in

patients with HSPC and are pleased to have our results meet the scientific

standards for presentation at this important congress."

    Sean Thompson, Director of Corporate Development and Norelin Project

Leader for YM BioSciences added, "We believe that Norelin has the prospect of

significant therapeutic and commercial potential for the treatment of HSPC.

YM BioSciences has filed a method-of-use and composition-of-matter patent for

Norelin(TM). The new formulation has the prospect of providing a safe,   

well-tolerated and long-lasting suppression of testosterone and PSA. All

complete responders in the proof-of-concept trial reported in May 2005 have

had castrate levels of testosterone and undetectable PSA for more than nine

months."

 

    About YM BioSciences

    YM BioSciences Inc. is a cancer product development company. Its lead

drug, tesmilifene, is a small molecule chemopotentiator currently undergoing a

700-patient pivotal Phase III trial in metastatic and recurrent breast cancer.

Published results from tesmilifene's first Phase III trial in the same

indication demonstrated a substantial increase in survival for women treated

with the combination of tesmilifene and chemotherapy compared to chemotherapy

alone, demonstrating that tesmilifene significantly enhanced the therapeutic

effect of chemotherapy. In addition to tesmilifene, the Company is developing

nimotuzumab, an anti-EGFr humanized monoclonal antibody for which Phase II

clinical data were released in 2005 in pediatric glioma and nasopharyngeal

cancer, and for which Phase III IND applications have been filed.

YM BioSciences is also developing its anti-GnRH, anti-cancer vaccine,

Norelin(TM), and in May 2005, the Company acquired DELEX Therapeutics Inc., a

private clinical stage biotechnology company developing AeroLEF(TM), a unique

inhalation delivered formulation of the established drug, fentanyl, to treat

acute pain including cancer pain. This product has completed a Phase IIa trial

with positive results and YM proposes to advance AeroLEF(TM) through a Phase

IIb pain trial in 2005. The company also has a broad portfolio of preclinical

compounds shown to act as chemopotentiators while protecting normal cells.

 

    Except for historical information, this press release may contain forward-

looking statements, which reflect the Company's current expectation regarding

future events. These forward looking statements involve risk and

uncertainties, which may cause but are not limited to, changing market

conditions, the successful and timely completion of clinical studies, the

establishment of corporate alliances, the impact of competitive products and

pricing, new product development, uncertainties related to the regulatory

approval process and other risks detailed from time to time in the Company's

ongoing quarterly and annual reporting.

 

   

    For further information: Enquiries: James Smith, the Equicom Group Inc.,

Tel. (416) 815-0700 x 229, Fax (416) 815-0080, Email:

jsmith(at)equicomgroup.com; Carolyn McEwen, YM BioSciences Inc., Tel.

(905) 629-9761, Fax (905) 629-4959, Email: ir(at)ymbiosciences.com

    (YM. YMI YMBA)

 

 

 

 

 

 



END

YM Bio.'b'ser1 (LSE:YMB)
Historical Stock Chart
From Jun 2024 to Jul 2024

YM Bio.'b'ser1 (LSE:YMB)
Historical Stock Chart
From Jul 2023 to Jul 2024